𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Meta-analysis of 123I-MIBG cardiac scintigraphy for the diagnosis of Lewy body–related disorders

✍ Scribed by Alisha E. King; Jim Mintz; Donald R. Royall


Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
158 KB
Volume
26
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Patients with parkinsonism pose a diagnostic challenge. Parkinson's disease may be difficult to distinguish from multiple system atrophy and progressive supranuclear palsy, whereas Parkinson's disease and dementia with Lewy bodies can be difficult to distinguish from Alzheimer's disease and other dementias. A number of studies have found diminished cardiac ^123^I‐metaiodobenzylguanidine uptake in Lewy body–related conditions (Parkinson's disease and Lewy body dementia). In 2005, the Dementia With Lewy Bodies Consortium considered ^123^I‐metaiodobenzylguanidine cardiac scintigraphy a “supportive” diagnostic feature, based on limited evidence. We report a meta‐analysis of the literature and an assessment of the utility of ^123^I‐metaiodobenzylguanidine for the diagnosis of dementia with Lewy bodies and Parkinson's disease. A search was conducted of articles published between 1950 and June 2010. Forty‐six studies involving neuropsychiatric and movement disorders, comprising 2680 subjects, were included in the analysis. A mixed‐effects regression model was used to analyze the delayed mean heart‐to‐mediastinum ratio of ^123^I‐metaiodobenzylguanidine uptake. ^123^I‐metaiodobenzylguanidine cardiac scintigraphy sensitively detected and specifically distinguished 2 diagnostic clusters: (1) Parkinson's disease, dementia with Lewy bodies, and rapid eye movement sleep behavior disorder; and (2) normal controls and patients with Alzheimer's disease, multiple system atrophy, progressive supranuclear palsy, vascular dementia, and frontotemporal dementia. The area under the receiver operating characteristic curve was 0.987 at a cluster discriminatory heart‐to‐mediastinum ratio threshold of 1.77. This threshold yielded 94% sensitivity and 91% specificity for the discrimination of these diagnostic clusters. ^123^I‐metaiodobenzylguanidine cardiac scintigraphy can accurately distinguish between 2 movement disorders, Parkinson's disease and multiple system atrophy, and between 2 common causes of dementia, Alzheimer's disease and dementia with Lewy bodies. © 2011 Movement Disorder Society


📜 SIMILAR VOLUMES


123I-MIBG cardiac scintigraphy in Lewy b
✍ Giorgio Treglia; Antonio Bagnato; Daniela Di Giuda; Alessandro Giordano 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB

Although we are sympathetic to Reynolds and Slocum's concerns, 1 their editorial errs on several points. The authors cite deference to regulatory (presumably Food and Drug Administration) approval as a constraint. The FDA has long recognized broad physician discretion in using FDAapproved drugs or d